« Previous
Next »
Titles
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight1
- Climate change: information on potential economic effects could help guide federal efforts to reduce fiscal exposure : report to Congressional requesters1
- DNA Research: Uncertain Peril and Certain Promise1
- Fundamentals of underwriting in the nongroup health insurance market: access to coverage and options for reform1
- Healthy People: The Surgeon General's Report on Health Promotion and Disease Prevention1
- Identification and care of those at highest risk of cancer1
- Internal urethrotomy: are the benefits to be derived from it, as now advocated for the relief of stricture, commensurate with its dangers?1
- Is the extirpation of the cancerous uterus a justifiable operation?1
- Medicare and Medicaid: CMS needs to fully align its antifraud efforts with the fraud risk framework : report to Congressional addressees1
- Medicare's use of risk adjustment1
- Testimony by David Baltimore for the Committee on Science and Technology1
- The medical adviser in life assurance1
- The relative value of certain obstetrical operations: embryotomy, Cesarean section, symphysiotomy1
- Vaginal hysterectomy for cancer1
- Veterans' health care: limited progress made to address concerns that led to high-risk designation : testimony before the Committee on Veterans' Affairs, U.S. Senate1
- X-rays... how safe!!1